Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review

  • ID: 4282126
  • SWOT Analysis
  • 50 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Daiichi Sankyo Co Ltd
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • MORE
Epizyme Inc (EPZM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the Author to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Epizyme, Inc. (Epizyme) is a biopharmaceutical company that develops novel epigenetic therapies for the treatment of cancer and other disorders. The company discovers and develops small molecule inhibitors of a class of enzymes, namely, histone methyl transferases (HMTs) and other chromatin modifying proteins (CMPs). Using its proprietary platform and collaborations, the company has initiated the identification and development of small molecule inhibitors of CMPs and HMTs. The company is developing product candidates for the treatment of solid tumors, non-hodgins lymphoma, mesothelioma, ovarian cancer, molecularly targeted tumors and sickle cell disease. Epizyme is headquartered in Cambridge, Massachusetts, the US.

Epizyme Inc Key Recent Developments

Aug 02,2018: Epizyme reports second quarter 2018 financial results and provides business updates
Jul 23,2018: Epizyme names Dr. Shefali Agarwal as Chief Medical Officer
May 08,2018: Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates
Mar 13,2018: Epizyme Reports Fourth Quarter and Full Year 2017 Financial Results
Mar 12,2018: Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Daiichi Sankyo Co Ltd
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • MORE
Section 1 - About the Company
Epizyme Inc - Key Facts
Epizyme Inc - Key Employees
Epizyme Inc - Key Employee Biographies
Epizyme Inc - Major Products and Services
Epizyme Inc - History
Epizyme Inc - Company Statement
Epizyme Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis
Company Overview
Epizyme Inc - Business Description
R&D Overview
Epizyme Inc - Corporate Strategy
Epizyme Inc - SWOT Analysis
SWOT Analysis - Overview
Epizyme Inc - Strengths
Epizyme Inc - Weaknesses
Epizyme Inc - Opportunities
Epizyme Inc - Threats
Epizyme Inc - Key Competitors

Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Epizyme Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments
Aug 02, 2018: Epizyme reports second quarter 2018 financial results and provides business updates
May 08, 2018: Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates
Mar 12, 2018: Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors
Nov 01, 2017: Epizyme Reports Third Quarter 2017 Operating Results and Company Updates
Aug 15, 2017: Epizyme Announces Leadership Transition for Finance Organization
Aug 04, 2017: Epizyme Reports Second Quarter 2017 Financial Results and Clinical and Business Progress
May 08, 2017: Epizyme Reports First Quarter 2017 Results and Provides Corporate Update
Mar 09, 2017: Epizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals
Mar 09, 2017: Epizyme President of Research and Chief Scientific Officer, Robert Copeland, Announces Retirement from the Company
Feb 07, 2017: Epizyme Elects Kevin Conroy to its Board of Directors

Section 6 – Appendix
Methodology
Ratio Definitions
About
Contact Us
Disclaimer

List of Tables
Epizyme Inc, Key Facts
Epizyme Inc, Key Employees
Epizyme Inc, Key Employee Biographies
Epizyme Inc, Major Products and Services
Epizyme Inc, History
Epizyme Inc, Subsidiaries
Epizyme Inc, Key Competitors
Epizyme Inc, Ratios based on current share price
Epizyme Inc, Annual Ratios
Epizyme Inc, Annual Ratios (Cont...1)
Epizyme Inc, Interim Ratios
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Epizyme Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Epizyme Inc, Performance Chart (2013 - 2017)
Epizyme Inc, Ratio Charts
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Takeda Pharmaceutical Co Ltd
  • Pfizer Inc
  • Novartis AG
  • Merck & Co Inc
  • Daiichi Sankyo Co Ltd
  • Constellation Pharmaceuticals Inc
  • AbbVie Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll